Health
MEI Pharma Reports Preclinical Data Demonstrating Ability of Voruciclib to Regulate MYC and Synergize with KRAS Inhibitors in KRAS Mutant Cancers – StreetInsider.com
SAN DIEGO, April 10, 2021 /PRNewswire/ — MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer,…
SAN DIEGO, April 10, 2021 /PRNewswire/ — MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced preclinical data demonstrating that voruciclib, an orally administered cyclin-dependent kinase (CDK) inhibitor that is potent against CDK9, has single agent activity against multiple KRAS mutant cancer cell lines and synergistically inhibits growth of KRAS mutant cancers in combination with KRAS inhibitors. The research is…
-
Noosa News18 hours agoThe Laundry Lady secures $1M to fuel international expansion
-
General22 hours agoEveryday AI use brings a hidden climate cost
-
Noosa News14 hours agoTruffle growers say rare delicacy is worth its $3,500 per kilo expense
-
Noosa News15 hours agoHomicide investigation underway after woman found dead in north Brisbane